Alphamab Oncology(HK:9966)
HK$5.75-0.20 (-3.36%)
HK:9966
Alphamab Oncology financials statements
HK$5.75
At close:-0.20 (-3.36%)
Want to see HK:9966 full AI Analyst Report?
Alphamab Oncology (9966) Income Statement
2 Followers
Alphamab Oncology Income Statement
Last quarter (Q2 2026), Alphamab Oncology's total revenue was ¥271.54M, an increase of 56.45% from the same quarter last year. In Q2, Alphamab Oncology's net income was ¥-40.51M. See Alphamab Oncology’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ¥ 551.58M | ¥ 640.08M | ¥ 218.77M | ¥ 166.84M | ¥ 146.02M | |
| ¥ 426.67M | ¥ 579.77M | ¥ 163.54M | ¥ 122.64M | ¥ 142.99M | |
| ¥ 575.99M | ¥ 479.26M | ¥ 487.09M | ¥ 555.18M | ¥ 558.91M | |
| Depreciation and Amortization | ¥ 64.68M | ¥ 77.03M | ¥ 69.12M | ¥ 55.19M | ¥ 41.10M |
| ¥ -84.64M | ¥ 178.04M | ¥ -129.30M | ¥ -377.18M | ¥ -358.13M | |
| ¥ -149.32M | ¥ 101.01M | ¥ -305.55M | ¥ -432.37M | ¥ -415.62M | |
| ¥ 38.33M | ¥ 65.84M | ¥ 112.96M | ¥ 106.82M | ¥ 3.50M | |
| ¥ -110.99M | ¥ 166.34M | ¥ -210.59M | ¥ -325.72M | ¥ -412.42M | |
| ¥ -110.99M | ¥ 166.34M | ¥ -210.59M | ¥ -325.72M | ¥ -412.42M | |
| Per Share Metrics | |||||
| Basic EPS | ¥ -0.12 | ¥ 0.17 | ¥ -0.22 | ¥ -0.35 | ¥ -0.44 |
| Diluted EPS | ¥ -0.12 | ¥ 0.17 | ¥ -0.22 | ¥ -0.35 | ¥ -0.44 |
| Weighted Average Shares Outstanding | 961.40M | 978.48M | 959.90M | 930.63M | 935.49M |
| Weighted Average Shares Outstanding (Diluted) | 961.40M | 984.19M | 959.90M | 936.50M | 935.49M |
Currency in CNY

